TRADENAME Boehringer Ingelheim Pty Ltd

Nerandomilast is proposed for the treatment of adult patients with Idiopathic Pulmonary Fibrosis (IPF; a chronic, progressive lung disease where the air sacs become scarred and thickened), for the treatment of Progressive Pulmonary Fibrosis (PPF; when there are signs of worsening lung scarring despite standard treatment) and for the reduction in the risk of death in adult patients with PPF.